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N-Glycosylation plays an important role in protein
folding and function. Previous studies demonstrate
that a phenylalanine residue introduced at the n-2
position relative to an Asn-Xxx-Thr/Ser N-glycosyla-
tion sequon increases the glycan occupancy of the
sequon in insect cells. Here, we show that any aro-
matic residue at n-2 increases glycan occupancy
in human cells and that this effect is dependent
upon oligosaccharyltransferase substrate prefer-
ences rather than differences in other cellular pro-
cessing events such as degradation or trafficking.
Moreover, aromatic residues at n-2 alter glycan pro-
cessing in the Golgi, producing proteins with less
complex N-glycan structures. These results demon-
strate that manipulating the sequence space sur-
rounding N-glycosylation sequons is useful both for
controlling glycosylation efficiency, thus enhancing
glycan occupancy, and for influencing the N-glycan
structures produced.
INTRODUCTION
N-Glycosylation is a prevalent co- and/or post-translational
modification of proteins that traverse the cellular secretory
pathway (Apweiler et al., 1999). N-Glycans play crucial roles in
protein homeostasis, modulating protein stability (Culyba et al.,
2011; Hanson et al., 2009; Hebert et al., 2014; Imperiali and Rick-
ert, 1995; Joao and Dwek, 1993; Price et al., 2012; Wang et al.,
1996; Wormald and Dwek, 1999), chaperone-mediated folding
(Hammond et al., 1994; Hebert et al., 2014; Helenius and Aebi,
2001; Jitsuhara et al., 2002; Oliver et al., 1997; Ou et al., 1993;
Schmaltz et al., 2011; Ware et al., 1995), vesicular trafficking
(Lu et al., 1997; Martina et al., 1998), and endoplasmic reticu-
lum-associated degradation (ERAD) (Parodi, 2000; Vembar and1052 Chemistry & Biology 22, 1052–1062, August 20, 2015 ª2015 ElBrodsky, 2008). N-Glycans also strongly influence biological
function, including immune/inflammatory responses and circu-
lating glycoprotein clearance, wherein carbohydrate binding
proteins (lectins) recognize specific glycoforms of glycoproteins
(Ahrens, 1993; Bertozzi and Kiessling, 2001; Chui et al., 2001;
Sorensen et al., 2012).
During N-glycosylation, the heteromeric oligosaccharyltrans-
ferase enzyme complex (OST) in the lumen of the ER catalyzes
the transfer of the Glc3Man9GlcNAc2 oligosaccharide from a do-
lichol phosphate donor to the side-chain amide nitrogen of an
acceptor Asn (Kornfeld and Kornfeld, 1985). Proteins translo-
cated into the ER are scanned by OST for the N-glycosylation
sequon Asn-Xxx-Ser/Thr (or, rarely, Asn-Xxx-Cys), where Xxx
is any residue but Pro, and upon recognition of this sequon,
the oligosaccharide is transferred to Asn either co- or post-trans-
lationally (Bas et al., 2011; Ruiz-Canada et al., 2009). Removal of
two terminal glucoses from the N-glycan by ER glucosidases al-
lows N-glycoproteins to engage the lectin chaperones calnexin
and/or calreticulin, promoting proper folding (Caramelo and Par-
odi, 2008). Once folded, N-glycoproteins are packaged into ves-
icles and proceed to the Golgi, where they can interact with
N-glycan processing enzymes that trim and elaborate glycans,
affording a complex array of glycoforms (Lowe and Marth,
2003; Nairn et al., 2008).
It is estimated that one-third of sequons are not occupied by
N-glycans (Apweiler et al., 1999; Petrescu et al., 2004; Surleac
et al., 2012). It is not known whether signals exist in the structure
of a protein that discourage OST from glycosylating proteins at a
site that would render them unfoldable. Similarly, it is not known
whether cues exist in a protein’s primary or secondary structure
that increase the glycosylation efficiency of OST for sequons in b
turns, a context that can lead to an increase in protein stability
(Culyba et al., 2011; Hanson et al., 2009; Price et al., 2011).
We have previously shown that introduction of a Phe residue at
the n-2 position relative to the Asn of a sequon stabilizes glyco-
sylated Rattus norvegicus cluster of differentiation 2 adhesion
domain (CD2ad), Homo sapiens muscle acylphosphatase, and
Homo sapiens Pin1 WW domain (Culyba et al., 2011; Hanson
et al., 2009; Price et al., 2011). This stabilization is due tosevier Ltd All rights reserved
Figure 1. Aromatic Residues at n-2 Decrease the Amount of Non-
glycosylated CD2ad and Increase the Amount of Secreted Glycosy-
lated CD2ad
(A) CD2ad expression constructs, both CD2-L (Leu) and CD2-Aro (Aromatic)
variants, allow for targeting to the secretory pathway via the PPTLS and
western blot analysis via the FLAG tag.
(B) Anti-FLAG western blots of HEK 293 cell lysate and media display bands
corresponding to glycosylated (green arrowheads) and non-glycosylated (blue
arrowheads) CD2ad variants. A faint nonspecific band is detected by anti-
FLAG in the cell lysate, as seen in the EGFP negative control lanes.
(C) Quantification of western blots shows that variants with EASs display less
non-glycosylated protein in cell lysate and media compared with CD2-L. Band
intensities are normalized to that of the CD2-L + glycan band. Solid bars
quantify glycosylated protein and open bars quantify non-glycosylated pro-
tein. Error bars indicate SDs from three biological replicates; **p < 0.01.
See also Figure S1.protein-carbohydrate interactions driven largely by dispersion
forces between Phe, the N-glycan, and Thr in the context of a
reverse turn (Chen et al., 2013). These forces create an enhancedChemistry & Biology 22, 1052–aromatic sequon (EAS) structural motif that can be incorporated
into glycosylation-naı¨ve proteins to confer glycosylation-depen-
dent native-state stabilization (Culyba et al., 2011). Phe at n-2
also increases glycan occupancy in CD2ad and muscle acyl-
phosphatase secreted from Sf9 insect cells (Culyba et al.,
2011), although it is not known whether this results from
decreased ERAD, increased folding and trafficking, or increased
OST glycosylation efficiency. Statistical analysis of the primary
sequence surrounding sequons indicates an increased occur-
rence of aromatic residues immediately preceding occupied se-
quons compared with unoccupied sequons (Petrescu et al.,
2004; Surleac et al., 2012), suggesting a potential OST prefer-
ence for aromatic residues at n-2. Moreover, the residue at n-2
must be Asp or Glu for bacterial OST to glycosylate a sequon,
demonstrating that this position can influence glycosylation effi-
ciency (Kowarik et al., 2006; Wacker et al., 2002).
Here, we report that human OST preferentially glycosylates
substrates containing EASs. We express the rat ortholog of
CD2ad, a protein that is natively glycosylation naı¨ve, without
or with an EAS containing Phe, His, Tyr, or Trp at n-2 in human
cells, and observe increased glycan occupancy for all CD2ad
EASs expressed in this human cell line. We also express a
protein, transthyretin (TTR), with a native sequon that is poorly
glycosylated, and observe an increase in glycan occupancy af-
ter introduction of Phe at n-2. To directly test the preference of
OST for Phe at n-2, and to remove any contributions of cellular
processing differences between differentially glycosylated pro-
teins, we express tandem repeats of two different N-glycopro-
teins, CD2ad and fibroblast growth factor 9 (FGF9), each as a
single polypeptide chain. These tandem repeat sequences
show that, for both N-glycoproteins, the EAS is a better OST
substrate than the standard sequon within the same polypep-
tide chain. Lastly, we report that EASs alter glycan processing,
with different residues at n-2, leading to different glycoform
product ensembles. Thus, our results show that the sequence
surrounding N-glycosylation sequons affects both OST-medi-
ated glycosylation and glycosyltransferase-mediated glycan
elaboration in the Golgi, suggesting that primary sequence
manipulation can be used to alter glycoprotein structure and
function.
RESULTS
EASs Increase Glycan Occupancy of CD2ad
To probe the effect of aromatic residues at n-2 on glycan occu-
pancy, we used the glycosylation-naı¨ve rat ortholog of CD2ad
as a model protein. Previously, we showed that an N-glycosyl-
ation sequon introduced into the type I b-bulge reverse turn of
CD2ad is glycosylated in Sf9 insect cells, and we determined
the folding energetics of its glycoforms (Culyba et al., 2011;
Hanson et al., 2009). However, the effects of EASs on glycan
occupancy in proteins expressed in human cells and the mech-
anisms involved are unknown. In HEK 293 cells, we expressed
variants of CD2ad containing an N-terminal preprotrypsin leader
sequence (PPTLS) to target the protein to the ER, an N-terminal
hexahistidine tag preceding a FLAG tag, and an Asp67Thr
mutation (to introduce an N-glycosylation sequon; Figure 1A).
The wild-type sequence surrounding the glycosylation site is
Leu63Ala64Asn65Gly66Thr67, with Leu at n-2 (CD2-L). We created1062, August 20, 2015 ª2015 Elsevier Ltd All rights reserved 1053
Figure 2. Phe at n-2 of D18GTTR Increases theGlycanOccupancy of
the Poorly Glycosylated Native Sequon of TTR
(A) Autoradiogram of immunoprecipitated [35S]D18G TTR variants from
HEK 293 cell lysates displays bands corresponding to glycosylated (green
arrowhead) and non-glycosylated (blue arrowhead) variants. Pulse-chase was
performed in the presence of 10 mM lactacystin, and samples were harvested
after a 3-hr chase.
(B) Quantification of bands shows that Phe at n-2 increases D18G TTR glycan
occupancy. Error bars indicate SDs from three biological replicates; **p < 0.01.
See also Figure S2.variants with Phe (CD2-F), His (CD2-H), Trp (CD2-W), or Tyr
(CD2-Y) at n-2 to determine whether these aromatic residues in-
crease glycan occupancy.
HEK 293 cells were transfected with expression vectors for
CD2ad variants, and cell lysates and media were harvested
3 days after transfection. For each sample, cell lysate (25 mg of
total protein) was subjected to SDS-PAGE and visualized by
anti-FLAG western blotting. Cell media samples were analyzed
similarly, where volumes loaded per lane were normalized to
corresponding cell lysate protein concentrations (Figure 1B).
The band intensities for glycosylated (green arrowheads) and
non-glycosylated (blue arrowheads) CD2ad variants were quan-
tified and normalized to the +glycan band of CD2-L (Figure 1C).
In cell lysates, the +glycan band (solid bars) is not significantly
affected by aromatic residues at n-2. However, the glycan
band (open bars) decreases for all aromatic variants. In media
samples, there is significantly more +glycan band for all
EAS-containing proteins and significantly less glycan band
for all EAS-containing proteins than for CD2-L. To ensure that
glycosylated and non-glycosylated species were correctly iden-
tified, all variants were digested with PNGase F to remove N-gly-
cans, causing the +glycan band intensities to decrease and
the glycan band intensities to increase (Figure S1). These re-
sults suggest that incorporating any aromatic residue at n-2
can increase N-glycan occupancy of proteins expressed in
human cells.
EASs Increase Glycan Occupancy of D18G
Transthyretin
We next attempted to boost the glycan occupancy of a poorly
glycosylated native sequon by introducing Phe at n-2. Transthyr-
etin (TTR) contains one native sequon in a type IV b turn,
Asn98Asp99Ser100, which is poorly glycosylated, owing both to
Asp at n+1 and Ser at n+2 (Kasturi et al., 1997). D18G TTR is
an amyloidogenic disease-associated mutant that is inefficiently
secreted and subject to ERAD (Hammarstrom et al., 2003; Seki-
jima et al., 2005). This variant has been shown to be post-trans-1054 Chemistry & Biology 22, 1052–1062, August 20, 2015 ª2015 Ellationally glycosylated by OST to prevent aggregation and facil-
itate degradation (Sato et al., 2012).
We expressed FLAG-tagged variants of D18G TTR in HEK 293
cells, one with the wild-type sequence Thr96Ala97Asn98
Asp99Ser100 and one with Phe at n-2 (T96F). We then performed
pulse-chase experiments in the presence of 10 mM lactacystin, to
minimize proteasomal degradation effects. After a 20-min pulse
and a 3-hr chase, cell lysates and media were harvested and
[35S]D18G TTR variants were immunoprecipitated with anti-
FLAG affinity resin and quantified by phosphorimaging. D18G
T96F glycan occupancy is twice that of D18G (0.12 ± 0.01 versus
0.06 ± 0.01) (Figures 2A and 2B). There is less total D18G than
D18GT96F, indicating that proteasomal inhibitionmaybe incom-
plete over the duration of the experiment or that D18G is being
degraded in another way (Figure S2A). PNGase F digestion of
samples causes the +glycan bands (green arrowhead) to disap-
pear, indicating that this band corresponds to glycosylated TTR
(Figure S2B). These results suggest that incorporating an EAS
can increase glycan occupancy of a poor native sequon.
EASs Increase Glycan Occupancy in Single-Chain
Tandem Repeats of CD2ad
The enhanced glycan occupancy of the EASs in CD2ad and TTR
could come not only from glycosylation preferences of OST but
also from differential intracellular processing. To determine
more directly whether OST preferentially glycosylates EASs, we
created single-chain tandem domain constructs that allow for
expression of two CD2ad sequences within a single polypeptide
chain. BecausebothCD2ad repeats are on the samepolypeptide
chain, they are unlikely to be differentially synthesized, trafficked,
or degraded. Each construct contained a PPTLS, a FLAG tag, a
CD2ad sequence, a tobacco etch virus (TEV) protease cleavage
site, a hemagglutinin (HA) tag, and a second CD2ad sequence
(Figure 3A). Quantitative comparison of the glycan occupancy
of each CD2ad from the same polypeptide allowed us to deter-
mine the contribution of OST preference for particular sequons
independent of other cellular processes. Four such constructs
were created: L-F, where the N-terminal CD2ad has Leu at n-2
and the C-terminal CD2ad has Phe at n-2; F-L, where the N-ter-
minal CD2ad has Phe at n-2 and the C-terminal CD2ad has Leu
at n-2; L-L, where both domains have Leu at n-2; and F-F, where
both domains have Phe at n-2.
At 3 days post-transfection in HEK 293 cells, cell lysates and
media were harvested and analyzed by western blotting. When
probed with either anti-FLAG antibody or anti-HA antibody, tan-
dem proteins exhibit three bands, corresponding to species with
two (red arrowheads), one (green arrowheads), or zeroN-glycans
(blue arrowheads) (Figure S3A). The disappearance of the higher
two bands following PNGase F digestion, and the appearance of
the lower band, confirms that the upper bands contain glycosy-
lated tandem proteins (Figure S3B). Total intensity for all three
bands was quantified for each sample to confirm that anti-
FLAG (solid bars) and anti-HA (open bars) antibodies reported
the same relative intensities (Figure S3C). In cell lysate samples,
total tandem protein remains constant across constructs. How-
ever, total tandem protein in cell media samples differs, in that
there is less L-L tandem protein and more F-F tandem protein
(Figure S3C), which may reflect the known native-state stabiliza-
tion provided by Phe at n-2 in CD2ad (Culyba et al., 2011).sevier Ltd All rights reserved
Figure 3. Single-Chain Tandem CD2ad Ex-
periments Confirm Preference of OST for
the EAS
(A) The tandem CD2ad cassette allows for
expression of two CD2ad variants within a single
polypeptide chain. Incubation with TEV protease
cleaves the single-chain tandem protein into an
N-terminal protein containing the FLAG epitope
and the first CD2ad and a C-terminal protein con-
taining the HA epitope and the second CD2ad.
(B) Anti-FLAG western blots of cell lysate and
media display bands corresponding to glycosy-
lated (green arrowheads) and non-glycosylated
(blue arrowheads) N-terminal CD2ad. Anti-HA
western blots display bands corresponding to
glycosylated (green arrowheads) and non-glyco-
sylated (blue arrowheads) C-terminal CD2ad.
(C) Quantification of western blots of cleaved
CD2ad shows that glycan occupancy is higher for
domains containing Phe at n-2 than for domains
containing Leu at n-2, independent of whether the
Phe-containing domain is N-terminal or C-terminal.
Uncorrected values are glycan occupancies
calculated from raw gel band intensities, and cor-
rected values are corrected for low TEV cleavage
efficiency of non-glycosylated tandem protein, as
explained in the text. Solid bars quantify glycan
occupancy of the N-terminal CD2ad and open bars
quantify glycan occupancy of the C-terminal
CD2ad. Error bars indicate SDs from three bio-
logical replicates; #p = 0.05, *p < 0.05, **p < 0.01.
See also Figure S3 and Tables S1 and S2.We next digested the tandem proteins in each cell lysate and
each cell media sample using TEV protease. Cleaved samples
were analyzed by western blot, where anti-FLAG reports on
the N-terminal CD2ad and anti-HA reports on the C-terminal
CD2ad (Figure 3B). Following TEV cleavage, the28-kDa bands
corresponding to uncleaved tandem proteins decrease in inten-
sity, and new 14-kDa bands appear corresponding to cleaved
proteins (Figure S3D). Glycan occupancy is higher for the CD2ad
with Phe at n-2 than for the CD2ad with Leu at n-2, regardless of
whether the Phe-containing CD2ad is at the N or C terminus in
cell lysate or media samples (Figure 3C).
The decrease in intensity of uncleaved tandem proteins in
lysate samples differs for the three 28-kDa tandem protein
bands, which correspond to doubly, singly, and non-glycosy-
lated tandem proteins, indicating that the efficiency of TEV
protease cleavage in lysate depends on the extent of glycosyl-
ation of the tandem proteins. TEV cleavage efficiency de-
creases with decreased glycosylation: doubly, singly, and
non-glycosylated tandem proteins have cleavage efficiencies
of 70%–80%, 40%–60%, and 5%–15%, respectively (Ta-
ble S1). We do not yet understand the cause of this differential
cleavage efficiency, but because each pair of domains is part
of a single polypeptide chain before TEV cleavage (Figure 3A),
direct comparisons of glycan occupancies between the
N- and C-terminal fragments following TEV cleavage are still
meaningful. The uneven TEV protease cleavage efficiencies
for a given tandem protein construct in lysate lead to over-rep-
resentation of the absolute sequon occupancies for both the
N- and C-terminal domains because of the relatively high
cleavage efficiency of the doubly glycosylated tandem pro-Chemistry & Biology 22, 1052–teins and the relatively low cleavage efficiency of the non-gly-
cosylated tandem proteins. However, the effect on the relative
glycan occupancies of the N- and C-terminal domains is
small. Furthermore, this direct comparison is independent of
differences in total protein concentrations between different
constructs (e.g., that more F-F is present than L-L), because
only domains cleaved from a single polypeptide chain are
analyzed.
We address the differential TEV cleavage efficiency in lysate
in two ways. First, we have attempted to correct the gel band
intensities of the 14-kDa glycosylated and non-glycosylated
N- and C-terminal domains by subtracting the excess band in-
tensity due to the high cleavage efficiency of the doubly glyco-
sylated tandem protein from the glycosylated band, and by
adding the deficient band intensity due to the low cleavage
efficiency of the non-glycosylated tandem protein to the non-
glycosylated band (Table S1). These corrections lower the
observed glycan occupancy by 0.2–0.3 in each case, but
the differences between the sequon occupancies of domains
with Leu at n-2 versus Phe at n-2 are maintained (Figure 3C,
corrected values). Second, we have increased TEV cleavage
efficiency by first immunoprecipitating tandem proteins from
cell lysates using anti-FLAG affinity resin. The extent to which
this increases the fraction of cleaved tandem protein is difficult
to assess because of interference from the anti-FLAG light
chain band, which is near the 28-kDa tandem protein bands
(Figure S3E, asterisk). Nevertheless, quantification of the
14-kDa bands corroborates that the glycan occupancy is
higher when Phe is the n-2 residue instead of Leu (compare
Figure S3F with Figure 3C).1062, August 20, 2015 ª2015 Elsevier Ltd All rights reserved 1055
Figure 4. Single-Chain Tandem FGF9 Experiments Confirm Prefer-
ence of OST for the EAS
(A) The tandem FGF9 cassette allows for expression of two FGF9 variants
within a single polypeptide chain. Incubation with TEV protease cleaves the
single-chain tandem protein into an N-terminal protein containing the V5
epitope and the first FGF9 and a C-terminal protein containing the HA epitope
and the second FGF9.
(B) Anti-V5 western blots of cell lysate andmedia display bands corresponding
to glycosylated (green arrowheads) and non-glycosylated (blue arrowheads)
N-terminal FGF9. Anti-HA western blots display bands corresponding to gly-
cosylated (green arrowheads) and non-glycosylated (blue arrowheads)
C-terminal FGF9.
(C) Quantification of western blots of cleaved FGF9 shows that glycan occu-
pancy is higher for domains containing Phe at n-2 than for domains containing
Leu at n-2 from cell lysates, independent of whether the Phe-containing
domain is N-terminal or C-terminal. Glycan occupancy in cell lysates is also
higher in general for the N-terminal FGF9 than for the C-terminal FGF9, as
highlighted in the A-A and F-F controls, independent of which residue is at n-2.
In cell media, the glycan occupancy of the N-terminal domain overshadows
EAS effects. Solid bars quantify glycan occupancy of the N-terminal FGF9 and
open bars quantify glycan occupancy of the C-terminal FGF9. Error bars
indicate SDs from three biological replicates; *p < 0.05, **p < 0.01.
See also Figure S4; Table S2.EASs Increase Glycan Occupancy in Single-Chain
Tandem Repeats of Fibroblast Growth Factor 9
To understand whether the OST preference for EASs is CD2ad
specific or more universal, we created analogous single-chain
tandem constructs using Homo sapiens fibroblast growth factor
9 (FGF9), a protein with a native EAS (Phe77Pro78Asn79Gly80
Thr81) within a type I b-bulge turn conformation, similar to that
of CD2ad (Culyba et al., 2011) (Figure 4A). Initial experiments
(data not shown) indicated that the Asn79-Gly80-Thr81 sequon
for FGF9 domains exhibited nearly 100% glycan occupancy, ir-
respective of the presence or absence of Phe at the n-2 position.
Therefore, the native Thr81 residue was mutated to Ser81. Modi-1056 Chemistry & Biology 22, 1052–1062, August 20, 2015 ª2015 Elfying the sequon to the less efficiently glycosylated Asn-Gly-Ser
decreased ‘‘baseline’’ glycan occupancy (Kasturi et al., 1995;
Petrescu et al., 2004) of the sequon to allow for a more sensitive
measurement of the effects of the EAS on glycan occupancy.
Four such constructs were created: A-F, where the N-terminal
FGF9 has Ala at n-2 and the C-terminal FGF9 has Phe at n-2;
F-A, where the N-terminal FGF9 has Phe at n-2 and the C-termi-
nal FGF9 has Ala at n-2; A-A, where both domains have Ala at
n-2; and F-F, where both domains have Phe at n-2. As is com-
mon practice when evaluating the effect of an amino acid side
chain on a process of interest, Ala was chosen as the n-2 residue
in the domains without an EAS to limit any side-chain contribu-
tions that might be introduced from other residues (Morrison
and Weiss, 2001). For these tandem constructs, a V5 epitope
precedes the N-terminal FGF9, and an HA epitope precedes
the C-terminal FGF9.
At 2 days post-transfection in HEK 293T cells, cell lysates and
media were harvested and analyzed by western blotting, as
before. When probed with either anti-V5 antibody or anti-HA
antibody, tandem proteins exhibit three bands, corresponding
to species with two (red arrowheads), one (green arrowheads),
or zero N-glycans (blue arrowheads) (Figure S4A). The disap-
pearance of the upper two bands following PNGase F digestion,
and the appearance of the lower band, confirms that the upper
bands contain glycosylated tandem proteins (Figure S4B). The
amount of tandem protein expressed between variants differs,
with less overall protein for the A-A and F-F variants than for
the A-F and F-A variants. However, total band intensity for
all three bands is the same whether reported by anti-V5
(solid bars) or anti-HA (open bars) for each tandem protein
(Figure S4C).
Following TEV cleavage, the40-kDa bands corresponding to
uncleaved tandem proteins decrease in intensity, and new
20-kDa bands appear corresponding to cleaved proteins (Fig-
ure S4D). The A-A and F-F controls indicate that the N-terminal
FGF9 has higher glycan occupancy than the C-terminal FGF9
(Figure 4C), which is likely because sequons close to the C termi-
nus are glycosylated relatively inefficiently (Ben-Dor et al., 2004;
Gavel and von Heijne, 1990; Shrimal et al., 2013b). Sequons near
the C terminus can be glycosylated post-translationally by only
the STT3B-containing isoform of OST, whereas internal sequons
can be glycosylated by both the STT3A- and STT3B-containing
isoforms of OST (Shrimal et al., 2013b). Thus, the lower effective
abundance of OST isoforms that are competent to glycosylate
C-terminal sequons could explain their lower glycan occupancy.
Nevertheless, in cell lysate samples, glycan occupancy is higher
for the cleaved FGF9 with Phe at n-2 than for the cleaved FGF9
with Ala at n-2, regardless of whether the Phe-containing FGF9
domain is at the N or C terminus (Figures 4B and 4C). In cell me-
dia samples, the N-terminal glycosylation preference of OST
overshadows EAS effects on sequon occupancy. These results
reinforce our hypothesis that OST prefers EASs; however, they
also suggest that EAS effects on glycan occupancy are context
dependent.
To quantify the effect of EASs on glycan occupancy, indepen-
dent of the effects of N- versus C-terminal domain placement,
we fitted the glycan occupancy data to linear models with an in-
dicator variable for the effect of Phe at n-2, an indicator variable
for the effect of C-terminal placement of the EAS, and ansevier Ltd All rights reserved
Figure 5. Aromatic Residues at n-2 Are En-
riched in Glycosylatable Proteins Compared
with Non-glycosylatable Proteins
The differential frequency of aromatic amino acids
(frequency at given position minus overall fre-
quency) for glycosylatable proteins that traverse
the secretory pathway (solid bars) and non-glyco-
sylatable proteins in the cytosol/mitochondria
(open bars) are plotted versus their position relative
to the Asn of N-glycosylation sequons. Error bars
indicate SD; *p < 0.01 for a large sample, one-
tailed test of the differences between binomial
proportions.
See also Figure S5.interaction term, to determine whether these effects are additive
or whether they modulate each other (see Supplemental Infor-
mation for details). These models fit the data well and indicate
that Phe at n-2 significantly increases glycan occupancy for
FGF9 lysate, FGF9 media, CD2ad lysate, and CD2ad media.
These models also indicate that the effect of the EAS is attenu-
ated for FGF9 when the EAS is present in the C-terminal domain.
This effect is not apparent in CD2ad. The results of the regres-
sion are summarized in Table S2.
EASs Are Selected for in Proteins that Can Be
N-Glycosylated
Given that OST glycosylation efficiency is increased in EASs, a
selection pressure may exist that favors aromatic amino acids
at n-2 in proteins that can be N-glycosylated (i.e., proteins that
traverse the secretory pathway). To evaluate this hypothesis,
wecompared the frequencies of amino acids in positions five res-
idues immediately before and after Asn-Xxx-Ser/Thr sequences
betweenproteins that canandcannot beN-glycosylated (‘‘glyco-
sylatable’’ versus ‘‘non-glycosylatable’’ proteins). We defined
glycosylatable proteins as those that have a gene ontology
(GO) annotation indicating that they reside in the ER, the Golgi,
the lysosome, the plasma membrane, or the extracellular space.
We defined non-glycosylatable proteins as those that have a GO
annotation indicating that they reside in the cytosol or the mito-
chondria. We excluded proteins present in both lists.
The final set of glycosylatable proteins comprises 3,076 pro-
teins, with a mean length of 562 amino acids. The sequences
of these proteins include 9,770 Asn-Xxx-Ser/Thr sequences
that are more than five residues away from the N and C termini,
for an overall occurrence rate of 0.62 sequons per 100 amino
acids. The final list of non-glycosylatable proteins consists of
3,198 proteins, with amean length of 575 amino acids. These se-
quences include 7,766 Asn-Xxx-Ser/Thr sequences that are
more than five residues away from the N and C termini, for an
overall occurrence rate of 0.45 Asn-Xxx-Ser/Thr sequences
per 100 amino acids.
The overall frequencies of aromatic amino acids (Phe, Tyr, Trp,
His) at all positions within the proteome are 0.109 and 0.097 for
glycosylatable and non-glycosylatable proteins, respectively.
The difference between the overall frequency of aromatic amino
acids and the frequency of aromatic amino acids at positions
near Asn-Xxx-Ser/Thr is shown in Figure 5 (raw frequency data
are shown in Figure S5.) For glycosylatable proteins, aromatic
amino acids are enriched generally in positions N-terminal to
potential sequons. The p values that result from testing the hy-Chemistry & Biology 22, 1052–pothesis that aromatic amino acids are more enriched at posi-
tions n-5 to n-1 in glycosylatable than in non-glycosylatable
proteins are <0.01 at all positions except for n-3, where there
is no discernible enrichment of aromatic amino acids (Figure 5).
This effect is especially strong at n-2, where the enrichment of
aromatic amino acids is approximately 4-fold higher in glycosy-
latable than in non-glycosylatable proteins (0.0346 ± 0.0036
versus 0.0081 ± 0.0035). This result shows that, on a genome-
wide scale, aromatic amino acids are favored at the n-2 position
relative to Asn-Xxx-Ser/Thr sequences in glycosylatable pro-
teins, consistent with the hypothesis that EASs are selected for
to improve OST glycosylation efficiency.
EASsAffect the N-Glycan Structures in CD2ad and FGF9
In addition to affecting OST glycosylation efficiency, aromatic
amino acids at n-2 alter the SDS-PAGE banding patterns of
glycosylated CD2ad harvested from cell media. Whereas glyco-
sylated, secreted CD2-L exhibits predominantly one band, aro-
matic variants exhibit two bands (Figure 1B; Figure S6A), which
collapse to the non-glycosylated size after digestion with
PNGase F (Figure S6B). We hypothesized that residues at n-2
might influence the activities of Golgi enzymes involved in
N-glycan processing, leading to different glycoform populations
that have different gel banding patterns.
We analyzed the glycan composition of CD2-L, CD2-F, and
CD2-H purified from HEK 293 media (Figure S6) using MALDI-
TOF-mass spectrometry (MS) glycoform analysis (Ceroni et al.,
2008; Jang-Lee et al., 2006). A multi-institutional assessment
of glycomics methodologies demonstrated that MALDI-TOF-
MS is a reliable method for relative quantification based on the
signal intensities of permethylated glycans, especially when
comparing signals over a small mass range within the same
spectrum (Wada et al., 2007). Therefore, while absolute quantifi-
cation of candidate N-glycans by this method is not strictly
possible, valuable quantitative information can be extracted
from MS data.
MALDI-TOF-MS demonstrated that CD2-L has a diverse array
of glycoforms, including 14.8% oligomannose, 53.9% hybrid,
and 31.3% complex N-glycans (Figures 6A [top panel] and 6B).
In the EAS-containing CD2-F variant, glycoforms are far more
homogeneous, comprising 91.7% oligomannose N-glycans
(Figures 6A [middle panel] and 6B). This observation is consis-
tent with previous work on the EAS-containing human ortholog
of CD2ad, which has been shown to retain the oligomannose gly-
coforms when expressed in Chinese hamster ovary cells (Recny
et al., 1992; Rudd et al., 1999; Wyss et al., 1995). CD2-H has a1062, August 20, 2015 ª2015 Elsevier Ltd All rights reserved 1057
Figure 6. Different Residues at n-2 Alter
Glycoform Populations of Secreted Variants
of CD2ad
(A) MALDI-TOF mass spectra of permethylated
N-glycans released by PNGase F digestion indi-
cate that CD2-L N-glycans are highly heteroge-
neous and comprise a diverse set of oligo-
mannose, hybrid, and complex structures. The
heterogeneity is greatly reduced for CD2-F N-gly-
cans, which are mainly oligomannose. The het-
erogeneity of CD2-H N-glycans is intermediate
between that of CD2-L and that of CD2-F. All
molecular ions are [M + Na]+. Putative structures
are based on composition, tandem MS, and
biosynthetic knowledge. Structures that show
sugars within a bracket have not been unequivo-
cally defined.
(B) Comparison of N-glycan peak intensities con-
firms the reduction in complex glycoforms for
CD2-F andCD2-H variants, comparedwith CD2-L.
See also Figure S6.glycoform population of intermediate complexity, with 46.1%oli-
gomannose, 39.0% hybrid, and 14.9% complex N-glycans (Fig-
ures 6A [bottom panel] and 6B).
Given that the MALDI-TOF-MS results indicate that CD2-F is
more homogeneous than CD2-L, it is perhaps surprising that
CD2-F runs as two bands on SDS-PAGE while CD2-L runs as
a single band. To further understand these observations, we
analyzed the gel-extracted upper and lower +glycan CD2-F gel
bands by MALDI-TOF-MS. We found that the upper band con-
tains multiple glycoforms (including oligomannose), whereas
the lower bandcontains only oligomannoseglycans (FigureS6C).
Thus, it appears that the oligomannose glycoforms of our CD21058 Chemistry & Biology 22, 1052–1062, August 20, 2015 ª2015 Elsevier Ltd All rights reseconstructs co-migrate with the more
processed hybrid and complex-type gly-
coforms up to a point, but when the oligo-
mannose glycoforms are highly enriched,
as they are in CD2-F, the excess runs as
a separate band. To corroborate this
notion, we treated purified samples of
CD2-F, CD2-L, and CD2-H with a1-2,3-
mannosidase (which catalyzes the hydro-
lysis of a1-2 and a1-3 linked mannose
residues from N-glycans). This treatment
changed the gel mobility of the lower
CD2-F +glycan band, while the mobilities
of all of the other CD2ad variant bands
were insensitive to mannosidase cleav-
age (Figure S6B). While it is clear that
the digestion of the N-glycans with man-
nosidase was not complete (since the
mobilities of the oligomannose glyco-
forms in the upper bands did not change),
this result nevertheless qualitatively cor-
roborates the MS findings that the oligo-
mannose glycoforms are highly enriched
in CD2-F.
To test whether EAS alteration of glyco-
form populations extends to other pro-teins, we used MALDI-TOF-MS to analyze the glycan composi-
tion of FGF9-A (with Ala at n-2) and FGF9-F (with Phe at n-2)
secreted from HEK 293F cells. FGF9-A and FGF9-F were ex-
pressed as fusions to non-glycosylated immunoglobulin G Fc
to allow affinity purification using Protein A (Figure S7). FGF9-A
has a more diverse array of glycoforms, including 6.0% oligo-
mannose, 2.0%hybrid, and 92.0%complex N-glycans, whereas
the EAS-containing FGF9-F variant has less glycoform heteroge-
neity, with 1.3% oligomannose, 20.9% hybrid, and 77.8% com-
plex N-glycans (Figures 7A and 7B).
Thus, in both CD2ad and FGF9, EASs alter Golgi elabo-
ration of N-glycans, shifting glycoform populations away fromrved
Figure 7. Different Residues at n-2 Alter
Glycoform Populations of Secreted Variants
of FGF9-Fc Fusions
(A) MALDI-TOF mass spectra of permethylated
N-glycans released by PNGase F digestion indi-
cate that FGF9-A N-glycans are more complex
than FGF9-F N-glycans. All molecular ions are [M +
Na]+. Putative structures are based on composi-
tion, tandem MS, and biosynthetic knowledge.
Structures that show sugars within a bracket have
not been unequivocally defined.
(B) Comparison of N-glycan peak intensities con-
firms the reduction in complex glycoforms for
FGF9-F compared with FGF9-A.
See also Figure S7.complex N-glycans and toward hybrid or oligomannose N-gly-
cans. These results indicate that the primary sequence sur-
rounding an N-glycosylation sequon modulates which glyco-
forms are produced.
DISCUSSION
N-Glycosylation greatly expands the functionality of the prote-
ome. The human N-glycome is muchmore complex than the hu-
man proteome (Bertozzi and Kiessling, 2001; Freeze, 2006), and
differences in glycan occupancy and glycoform diversity exist
between copies of the same protein produced by a given cell.
A vast N-glycan processing network containing more than 100
enzymes affects both glycosylation efficiency and subsequent
N-glycan processing. Deficiencies in this network account for
many congenital disorders of glycosylation (Chui et al., 1997;
Jaeken, 2010; Shrimal et al., 2013a) and loss-of-function dis-
eases (Glozman et al., 2009), while alterations can generate
new biological function. Thus, variability in glycan occupancy
and diversity strongly influence biological function.Chemistry & Biology 22, 1052–1062, August 20, 2015We have shown that the primary
sequence surrounding an N-glycosylation
sequon strongly affects how efficiently
it is glycosylated by OST. EASs are
preferred by OST, exhibit higher glycan
occupancy, and can result in native-state
stabilization (Culyba et al., 2011; Hanson
et al., 2009; Price et al., 2011). OST may
therefore have evolved to prefer EASs,
because of the likelihood that glycosylat-
ing such proteins would stabilize the
native state and increase the overall levels
of functional protein.
We have also shown that the primary
sequence surrounding a sequon in a
folded protein can strongly affect
N-glycan processing. The extent to which
an N-glycan is processed is determined,
at least in part, by the accessibility of the
N-glycan to the Golgi-resident glycan
elaboration and/or trimming enzymes
(Hsieh et al., 1983; Hubbard, 1988; Rudd
et al., 1999; Thaysen-Andersen andPacker, 2012; Trimble et al., 1983). Based on the decrease in
complex-type glycoforms exhibited in EAS-containing variants
of CD2ad and FGF9, it appears that an interaction between an
N-glycan and a single residue side chain, like the interaction be-
tween the N-glycan and an aromatic side chain in an EAS (Chen
et al., 2013; Culyba et al., 2011; Price et al., 2011), can decrease
the dynamic accessibility of an N-glycan enough to profoundly
alter the extent to which it is processed in the Golgi.
Since EASs are excellent substrates for OST-mediated glyco-
sylation and can reduce glycan elaboration in the secretory
pathway, EASs can influence both intrinsic protein stabilization
and the N-glycan structures produced. EASs can be engineered
into therapeutic proteins to increase stability, glycan occupancy,
and glycoform homogeneity, boosting total protein yields
and decreasing immunogenicity. In addition, manipulating the
sequence space surrounding N-glycosylation sequons in
therapeutic proteins may provide control over half-life and clear-
ance by shifting glycoform populations toward or away from
structures that can be cleared by lectins (Sorensen et al.,
2012). There are likelymany other primary and secondary proteinª2015 Elsevier Ltd All rights reserved 1059
structure effectors of the glycoproteome that are yet to be
discovered. Further exploration of the EAS, and perhaps the
flanking sequence, should elucidate engineering guidelines for
enhancing glycosylation by OST and provide strategies for con-
trolling glycan structural homogeneity. This structure-based
approach offers the exciting prospect of manipulating protein
stability, immunogenicity, targeting, and a host of other proper-
ties conveyed by protein N-glycosylation.
SIGNIFICANCE
N-Glycosylation, the OST-mediated conjugation of oligo-
saccharides onto the Asn side-chain NH of proteins, occurs
in the majority of proteins that pass through the cellular
secretory pathway. These N-glycans add an additional level
of functional and structural diversity to the eukaryotic prote-
ome. N-Glycans affect protein folding intrinsically through
native-state protein-glycan interactions and extrinsically
by influencing N-glycoprotein engagement with proteosta-
sis network pathways, including chaperone-mediated
folding and proteasomal degradation pathways. N-Glycans
also engage with glycan binding proteins, affecting myriad
biological processes. Herein we report that incorporating
an aromatic amino acid (Phe, Tyr, His, or Trp) at the n-2 po-
sition relative to an N-glycosylation sequon, thereby
creating an EAS, increases sequon occupancy, due to OST
substrate preferences rather than differences in other
cellular processing events such as degradation or traf-
ficking. Moreover, the preference for aromatic amino acids
at the n-2 position is evident not only biochemically but
also evolutionarily, given the increased frequency of aro-
matic amino acids in this position in glycosylatable versus
non-glycosylatable proteins. The EAS also influences the
composition of the attachedN-glycans by altering glycan re-
modeling in the Golgi. The tandem domain experimental
approach employed is also significant because it should
be useful for further exploration of the sequence prefer-
ences of OST and those of the Golgi N-glycan processing
enzymes. In summary, this approach offers the opportunity
to manipulate N-glycoprotein structure, stability, immuno-
genicity, and targeting, thereby augmenting protein thera-




Standard protocols were used for vector construction. In brief, all expres-
sion constructs were cloned into vectors allowing for cytomegalovirus
promoter-driven transcription. Mutations were introduced via QuikChange
site-directed mutagenesis (Agilent Technologies 200515). The protocols
for vector construction are described in detail in Supplemental Experimental
Procedures.
Cell Culture
CD2ad-containing proteins were produced from HEK 293 cells transfected
with FuGENE 6 (Roche 11814443001) and cultured as monolayers in
D-MEM/F12 (Gibco 11330032) supplemented with 1% penicillin-strepto-
mycin-glutamine (Gibco 10378-016) and 10% fetal bovine serum (Omega Sci-
entific FB-02) media under standard conditions. TandemFGF9 repeat proteins
were produced from HEK 293T cells transfected with Xtreme Gene 9 (Roche1060 Chemistry & Biology 22, 1052–1062, August 20, 2015 ª2015 El06365787001) and cultured as described above. FGF9-Fc fusions were pro-
duced from suspension HEK 293F cells transfected with 293Fectin (Invitrogen
12347-019) and cultured in FreeStyle 293 (Invitrogen 12338) under standard
conditions. A detailed protocol for the pulse-chase experiments is available
in Supplemental Experimental Procedures.
Purification of CD2ad and FGF9 Variants
CD2-L, CD2-F, and CD2-H were expressed as described above. Media
from transfected cells were harvested every 2 days, and cells were split
and expanded as necessary to maintain 50%–80% confluency. Total har-
vested media volume for each variant was 500 ml. Urea powder was
added to media samples to 8 M to denature proteins and reduce interac-
tions between CD2ad variants and BSA or other secreted proteins. Vari-
ants were purified from denatured media samples by fast protein liquid
chromatography. Samples were first run over 5-ml Histrap FF columns
(GE Healthcare 17-5255-01) in 8 M urea, 150 mM NaCl, and 30 mM
Bis-Tris (pH 6.8). CD2ad was eluted with a linear gradient of imidazole.
Fractions containing CD2ad were pooled and concentrated in Amicon
Ultra-15 Centrifugal Filter Units (Millipore UFC901008). 1 mM tris-(2-car-
boxyethyl)phosphine (TCEP) was added to concentrated samples, which
were then purified by size-exclusion chromatography in 8 M urea,
30 mM Tris (pH 7.4) and 0.5% SDS using a Superdex 200 column (GE
Healthcare 17-5175-01). Fractions containing CD2ad were again concen-
trated, dialyzed against 50 mM ammonium bicarbonate (pH 8.4), and
lyophilized. Samples were analyzed for purity by SDS-PAGE and silver
staining (Pierce 21642).
FGF9-A and FGF9-F were expressed in HEK 293F suspension cultures, har-
vested 6 days after transfection, and centrifuged at 6,0003 g for 30min to pel-
let cells before filtering by 0.22-mm filter to remove residual cells. Supernatant
was run over a 5-ml HiTrap Protein A column (GE 17-0403-01), and Fc-fusion
proteins were eluted with 0.1 M Glycine (pH 2.7). Following dialysis into PBS,
purified Fc-fusion proteins were analyzed for purity by SDS-PAGE and
Coomassie blue staining.
Western Blotting
Three days post-transfection for CD2ad proteins and 2 days post-transfec-
tion for FGF9 proteins, media were harvested and centrifuged at 1,000 3
g for 2 min to pellet cell contaminants, after which the supernatant was trans-
ferred to fresh tubes. Cells were harvested at the same time from culture
dishes by trypsinization (Gibco 12605-010) and centrifuged at 1,000 3 g
for 2 min. Cell pellets were washed with Dulbecco’s PBS (DPBS) (Gibco
14190-136) and lysed in lysis buffer (DPBS, 1% Triton X-100, 1 mM EDTA)
for 30 min at 4C. Lysed cells were centrifuged at 10,000 3 g for 10 min,
and post-nuclear supernatants were transferred to fresh tubes. Total protein
in cell lysates was quantified by Micro BCA (Thermo Scientific 23235). For
PNGase F digests, samples were incubated with 1 ml of PNGase F (NEB
P0704S) for 2 hr at 37C, according to the manufacturer’s instructions. For
TEV digests, samples were incubated with 2 ml of AcTEV Protease (Invitrogen
12575-015) at 30C overnight, according to the manufacturer’s instructions.
For mannosidase digests, purified CD2ad variants (25 ng) were incubated
with 0.5 ml of a1-2,3 mannosidase (NEB P0729S) for 2 hr at 37C, according
to the manufacturer’s instructions. For CD2ad single-domain constructs and
CD2ad and FGF9 tandem constructs, Laemmli buffer containing 1 mM TCEP
was added to 25 mg of lysate per sample, and media sample volumes were
proportional to the total protein concentrations of their respective lysates.
For tandem constructs, Laemmli buffer containing 1 mM TCEP was added
to 10 mg of lysate per sample, and media sample volumes were proportional
to the amount of cells present in their respective lysates. For purified CD2ad
variants, Laemmli buffer containing 1 mM TCEP was added to 25 ng of pu-
rified protein. Lanes labeled ‘‘C’’ contain 20 ng of non-glycosylated CD2ad
control expressed in and purified from Escherichia coli (Culyba et al.,
2011). All samples were boiled in Laemmli buffer for 5 min and subjected
to SDS-PAGE using 4%–12% or 12% NuPAGE Novex Bis-Tris pre-cast
gels (Invitrogen NP0323BOX, NP0343BOX) and MOPS running buffer (Invi-
trogen NP0001). Proteins were transferred to nitrocellulose membranes,
which were stained with Ponceau S to visualize sample loading and transfer.
Western blotting then proceeded using Odyssey blocking buffer (LI-COR
927-40000) and mouse anti-FLAG antibody (Agilent 200472-21, 1:2000),sevier Ltd All rights reserved
mouse anti-HA antibody (Covance MMS-101P, 1:2000), or mouse anti-V5
antibody (Life Technologies R960-25, 1:5000). Proteins were visualized and
quantified using goat anti-mouse IRDye 800CW (LI-COR 827-08364,
1:15,000) and the Odyssey Infrared Imaging System.
Glycomic Analysis
Glycomic analysis was carried out using GlycoWorkBench according to
previous protocols (Ceroni et al., 2008; Jang-Lee et al., 2006). A detailed pro-
tocol for the glycomic analysis is available in Supplemental Experimental
Procedures.
Linear Regression Models and Amino Acid Frequency Analysis
Detailed protocols for the linear regression modeling of glycan occupancies
and amino acid frequency analysis are available in Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2015.06.017.
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